10/20/20 8:30 AMNASDAQ : JAGXReminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer"Leading Oncologists, Supportive Care Experts, and Patient Advocates Discuss Importance of Supportive Care for Cancer Patients and Address Debilitating Diarrhea Resulting from Cancer Therapy Virtual Event and Q&A 3:00 PM to 4:30 PM EDT on October 20 Registration Open for Financial and BusinessRHEA-AIneutral
10/16/20 4:15 PMNASDAQ : JAGXJaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective October 13, 2020, the Company has granted nonstatutory stock options for the purchase of up to 45,000 shares of the Company's common stock to one newRHEA-AIvery positive
10/15/20 8:30 AMNASDAQ : JAGXNapo Pharmaceuticals, a Subsidiary of Jaguar Health, Launches Web-based NapoCares Platform to Enhance Patient Access to MytesiJaguar Health, Inc. (NASDAQ:JAGX) announced today that its wholly owned subsidiary, Napo Pharmaceuticals, Inc.RHEA-AIvery positive
10/14/20 8:30 AMNASDAQ : JAGXJaguar Health and Its Subsidiary Bolster Management Team with Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs & Quality AssuranceOctober 14,RHEA-AIvery positive
10/13/20 8:30 AMNASDAQ : JAGXJaguar Health Provides Updates Regarding Company Capitalization StrategyJaguar Has Closed on the First $6 Million Tranche of the Previously Announced Non-Dilutive Royalty Financing Transaction - Which Now Has the Potential to Total $17 Million Jaguar and its Subsidiary, Napo Pharmaceuticals, Enter into Fourth Amendment to the Accounts Receivable Purchase Agreement withRHEA-AIneutral
10/07/20 8:30 AMNASDAQ : JAGXJaguar Health Subsidiary Napo Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Crofelemer (Mytesi) for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer TherapyA Significant Proportion of Patients Receiving Targeted Cancer Therapy Experience Diarrhea Initial Tranche of Non-dilutive Financing Transaction Increased from $5 Million to $6 Million by Mutual Consent with Lender, Providing Additional Q4 2020 Funding for Pivotal Phase 3 Clinical Trial and a TotalRHEA-AIneutral
10/06/20 8:30 AMNASDAQ : JAGXJaguar Health Meets Financial Condition for Sale of Royalty Rights for Mytesi (Crofelemer) IndicationsFinancial Condition for Initial $5 Million Tranche of Potential $16 Million Non-dilutive Financing Transaction Achieved through the Establishment of an At-the-Market Program Yesterday for Potential Future Financing Needs, if Any, with Ladenburg Thalmann Aggregate Royalty Proceeds of Potential $16RHEA-AIvery positive
10/02/20 8:30 AMNASDAQ : JAGXJaguar Health's Mental Health Entheogen Therapeutics Initiative Targets Plant-based Candidate Compound for Possible Schizophrenia and Psychoses IndicationsJaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's recently launched mental healthRHEA-AIpositive
10/01/20 8:30 AMNASDAQ : JAGXJaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 MillionRHEA-AIvery positive
09/28/20 8:30 AMNASDAQ : JAGXJaguar Health Subsidiary Napo Pharmaceuticals Sponsoring 2020 National Trans Visibility MarchJaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), is a proud sponsor of this year'sRHEA-AIneutral
